FY2025 · ended Dec 31, 2025 · Revenue $1.40B, +17.5% YoY · Filed Feb 25, 2026
Penumbra, Inc (PEN) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.4 billion and net income of $177.7 million. Free cash flow was $174.9 million. As of Sep 30, 2026 it held $673.6 million in cash and investments and $209.4 million in total debt.
Revenue (TTM)
$1.56B
+17.0% vs year-ago TTM
Net income (TTM)
$157.02M
-4.3% vs year-ago TTM
Operating cash flow (TTM)
$261.05M
+28.4% vs year-ago TTM
Free cash flow (TTM)
$200.29M
+31.2% vs year-ago TTM
EPS (TTM)
$3.97
-4.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
39.24M
+1.9% vs prior year
Net cash
$464.22M
as of Sep 30, 2026
Operating margin
12.1%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PEN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1321732
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.2B | $1.1B | $847.1M | $747.6M |
| Operating income | $189.2M | $9.3M | $73.6M | $6.1M | -$7.5M |
| Net income | $177.7M | $14.0M | $91.0M | -$2.0M | $5.3M |
| Diluted EPS | $4.52 | $0.36 | $2.32 | -$0.05 | $0.14 |
| Operating cash flow | $238.7M | $168.5M | $97.3M | -$55.7M | $9.5M |
| Free cash flow | $174.9M | $147.3M | $82.1M | -$75.0M | -$11.7M |
| Total assets | $1.8B | $1.5B | $1.6B | $1.4B | $1.2B |
| Total liabilities | $398.9M | $382.2M | $377.4M | $372.0M | $290.3M |
| Stockholders' equity | $1.4B | $1.2B | — | — | $953.9M |
| Cash and investments | $544.8M | $340.1M | $289.2M | $188.0M | $254.9M |
| Total debt | $219.7M | $223.4M | $234.3M | $235.8M | $173.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 7, 2026 | May 6, 2026 |
All 955 Penumbra, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.